3 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 2, Unknown 2, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 4 | Unknown 2, Completed 1, Recruiting 1 |
Follow Metastatic Sarcoma: new trials by email Literature Review of Metastatic Sarcoma trials Research Report on Metastatic Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer 64Cu-LNTH-1363S - Metastatic Sarcoma, Esophageal Cancer | Phase 1 / Phase 2 | Recruiting | Lantheus Medical Imaging | 26 | 2025-08-01 | 2025-08-12 |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Gemcitabine, Docetaxel, 9-ING-41 - Sarcoma, Soft Tissue Sarcoma | Phase 2 | Withdrawn | Brown University | 2021-09-01 | 2021-07-28 | |
| Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2021-05-03 | 2026-11-12 |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Avapritinib - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-01-20 | 2026-06-11 |
| Mix Vaccine for Metastatic Sarcoma Patients Mix vaccine - Metastatic Sarcoma, Reaction - Mixed Vaccine | Phase 1 / Phase 2 | Completed | Fuda Cancer Hospital, Guangzhou | 30 | 2017-11-30 | 2019-09-12 |
| Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma NC 6300 - Solid Tumor, Soft Tissue Sarcoma | Phase 1 / Phase 2 | Unknown | NanoCarrier Co., Ltd. | 150 | 2017-06-30 | 2020-02-28 |
| A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas PM01183, Doxorubicin, Gemcitabine - Metastatic Sarcoma | Phase 2 | Completed | Massachusetts General Hospital | 42 | 2015-08-01 | 2021-03-03 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) CMB305, atezolizumab - Sarcoma, Myxoid/Round Cell Liposarcoma | Phase 2 | Terminated | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 89 | 2015-04-29 | 2020-07-07 |
| A Study of SB939 in Patients With Translocation-Associated Recurrent/Metastatic Sarcomas SB939 - Metastatic Sarcoma | Phase 2 | Completed | NCIC Clinical Trials Group | 24 | 2010-10-21 | 2023-08-04 |
Sarcoma (10) · Colorectal Neoplasms (2) · Liposarcoma (2) · Sarcoma, Synovial (2) · Bone Neoplasms (1) · Chondrosarcoma (1) · Dermatofibrosarcoma (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Esophageal Neoplasms (1) · Gastrointestinal Stromal Tumors (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Liposarcoma, Myxoid (1) · Lung Neoplasms (1)
Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms, Connective and Soft Tissue (10) · Neoplasms, Connective Tissue (4) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms by Site (3) · Colonic Diseases (2) · Intestinal Diseases (2) · Intestinal Neoplasms (2) · Neoplasms, Adipose Tissue (2) · Rectal Diseases (2) · Bone Diseases (1)
Doxorubicin (2) · Gemcitabine (2) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Biopsy (1) · Docetaxel (1) · Immunotherapy, Active (1) · Magnetic Resonance Spectroscopy (1) · NC 6300 (1) · PM 01183 (1) · Rogaratinib (1) · Specimen Handling (1) · atezolizumab (1) · avapritinib (1) · envafolimab (1)
Brown University (1) · Fuda Cancer Hospital, Guangzhou (1) · Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Lantheus Medical Imaging (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · NCIC Clinical Trials Group (1) · NanoCarrier Co., Ltd. (1) · National Cancer Institute (NCI) (1) · Tracon Pharmaceuticals Inc. (1)
United States (8) · Canada (1) · China (1)
Atsushi Osada (1) · Bradley DeNardo, MD (1) · Don S Dizon, MD (1) · Gregory Cote, MD PhD (1) · James Freddo, MD (1) · Jordi Rodon Ahnert (1) · Quincy Chu (1) · Suzanne George (1)
PMID 25632070, PMID 31896519, PMID 34260265, PMID 35920783, PMID 38573872, PMID 42191879
UM1CA186709 (1)